December 3, 2009 - Development of a monoclonal antibody for the treatment of Alzheimer’s disease - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced an exclusive global licensing agreement with The Rockefeller University (New York, NY) concerning a novel monoclonal antibody, targeting certain specific forms of the Amyloid Beta parenchymal plaque for the treatment of Alzheimer’s disease.The anti-Amyloid Beta (ABeta) antibody therapy is a highly attractive approach to prevent and reverse the amyloid plaque formation which may lead to cognitive improvement in patients with Alzheimer’s disease. This antibody is planned to enter development at the end of 2009.
“It’s a great pleasure to interact with The Rockefeller University and in particular with Dr. Jeffrey Ravetch, a worldwide expert in the engineering of mAb Fc region and effector functions”... Sanofi-aventis' Press Release -
